Weil Company’s Sarepta Therapeutics SRPT Stock Holding History

Weil Company’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-70	Closed	-$5K	–	295
2019 Q3	$5K	Buy	+70	New	+$8.27K	﹤0.01%	340

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Weil Company's SRPT Position: Q4 2019 in Review

Weil Company sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 70 shares — an estimated $5K sold.

Weil Company first reported a position in SRPT in Q3 2019 and held it in 1 quarter. The position peaked at $5K in Q3 2019. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

Weil Company reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
Weil Company sold 70 Sarepta Therapeutics shares in Q4 2019, an estimated $5K.
Weil Company first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 1 quarter.
Weil Company's Sarepta Therapeutics position peaked at $5K in Q3 2019.
389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Weil Company's 13F filing for Q4 2019, filed 13 Feb 2020.